Similar content being viewed by others Introduction Type 2 diabetes mellitus (T2DM) and obesity pose a growing challenge to public health, with millions of people affected by these pathological conditions and socio-economic costs steadily increasing worldwide
They mimic or amplify GLP-1s effects in the body: Reduce hunger and increase fullness Improve insulin response and prevent blood sugar spikes Slow digestion to regulate appetite and glucose Support weight management when paired with lifestyle changes Reduce cardiovascular risks in some patients These medications stay active longer than natural GLP-1, giving consistent support for glucose and appetite control
Design stacks with clear protocols for dosing, timing, cycling, start low, titrate to response, time around workouts and sleep, and off-cycle to minimize tolerance and long-term risk
IBX joined other major insurers like Kaiser Permanente, Blue Cross Blue Shield of Michigan, Mass Health, North Carolinas State Health Plan and others in restricting or dropping coverage for GLP-1 medications
